Jing Zhang1, Yahong Wang, Quangui Yin, Wei Zhang, Tongxian Zhang, Yun Niu. 1. Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education and Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin 300060, China.
Abstract
BACKGROUND: Triple negative breast cancer (TNBC) is heterogeneous and considered as an aggressive tumor. This study was to evaluate the associated classification and its correlations with prognosis and the response to chemotherapy in Chinese women. METHODS: Four hundred and twenty-eight cases of invasive TNBC were involved in this study. The expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin 5/6 (CK5/6), Ki67 and p53 were analyzed by immunohistochemistry and compared with patient outcome, and its implications and chemotherapy response were evaluated in four subgroups: typical medullary carcinoma (TMC), atypical medullary carcinoma (AMC), non-specific invasive ductal carcinoma (IDC) and other types. RESULTS: The factors of tumor grade, tumor stage, lymph node status, EGFR/CK5/6 status and p53 labeling index were different among the groups. TMC tumors had the lowest rate of relapse (5.8%), while AMC, IDC and other types were associated with an increased risk of relapse (19.1%, 26.7% and 38.2% respectively). Many factors were risk predictors of relapse for TNBC and IDC, while only positive lymph node was for AMC. For MC tumors, adjunctive chemotherapy decreased the risk of relapse in lymph node positive subgroup (36.8% and 66.7%), while not significant in lymph node negative one (8.1% and 10.0%). CONCLUSION: The classification based on histologic and IHC findings may be a significant improvement in predicting outcome in TNBC. The different chemotherapy response in subgroups may contribute to guiding the treatment of TNBC.
BACKGROUND: Triple negative breast cancer (TNBC) is heterogeneous and considered as an aggressive tumor. This study was to evaluate the associated classification and its correlations with prognosis and the response to chemotherapy in Chinese women. METHODS: Four hundred and twenty-eight cases of invasive TNBC were involved in this study. The expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin 5/6 (CK5/6), Ki67 and p53 were analyzed by immunohistochemistry and compared with patient outcome, and its implications and chemotherapy response were evaluated in four subgroups: typical medullary carcinoma (TMC), atypical medullary carcinoma (AMC), non-specific invasive ductal carcinoma (IDC) and other types. RESULTS: The factors of tumor grade, tumor stage, lymph node status, EGFR/CK5/6 status and p53 labeling index were different among the groups. TMCtumors had the lowest rate of relapse (5.8%), while AMC, IDC and other types were associated with an increased risk of relapse (19.1%, 26.7% and 38.2% respectively). Many factors were risk predictors of relapse for TNBC and IDC, while only positive lymph node was for AMC. For MCtumors, adjunctive chemotherapy decreased the risk of relapse in lymph node positive subgroup (36.8% and 66.7%), while not significant in lymph node negative one (8.1% and 10.0%). CONCLUSION: The classification based on histologic and IHC findings may be a significant improvement in predicting outcome in TNBC. The different chemotherapy response in subgroups may contribute to guiding the treatment of TNBC.
Authors: R C Zellars; S G Hilsenbeck; G M Clark; D C Allred; T S Herman; G C Chamness; R M Elledge Journal: J Clin Oncol Date: 2000-05 Impact factor: 44.544
Authors: M Colleoni; N Rotmensz; G Peruzzotti; P Maisonneuve; G Viale; G Renne; C Casadio; P Veronesi; M Intra; R Torrisi; A Goldhirsch Journal: Ann Oncol Date: 2004-11 Impact factor: 32.976
Authors: J P Sloane; I Amendoeira; N Apostolikas; J P Bellocq; S Bianchi; W Boecker; G Bussolati; D Coleman; C E Connolly; V Eusebi; C De Miguel; P Dervan; R Drijkoningen; C W Elston; D Faverly; A Gad; J Jacquemier; M Lacerda; J Martinez-Penuela; C Munt; J L Peterse; F Rank; M Sylvan; V Tsakraklides; B Zafrani Journal: Virchows Arch Date: 1999-01 Impact factor: 4.064
Authors: Nadia P Castro; Maria C Rangel; Anand S Merchant; Gabriel MacKinnon; Frank Cuttitta; David S Salomon; Young S Kim Journal: Cancer Prev Res (Phila) Date: 2019-01-24
Authors: F Giugliano; J Uliano; V A A Zia; D Trapani; A Marra; G Viale; E Ferraro; A Esposito; C Criscitiello; P D'amico; G Curigliano Journal: Breast Cancer Res Treat Date: 2021-05-27 Impact factor: 4.872
Authors: Tim N Beck; Rachel Georgopoulos; Elena I Shagisultanova; David Sarcu; Elizabeth A Handorf; Cara Dubyk; Miriam N Lango; John A Ridge; Igor Astsaturov; Ilya G Serebriiskii; Barbara A Burtness; Ranee Mehra; Erica A Golemis Journal: Mol Cancer Ther Date: 2016-08-09 Impact factor: 6.261
Authors: Rong Bu; Abdul K Siraj; Khadija A S Al-Obaisi; Shaham Beg; Mohsen Al Hazmi; Dahish Ajarim; Asma Tulbah; Fouad Al-Dayel; Khawla S Al-Kuraya Journal: Int J Cancer Date: 2016-05-03 Impact factor: 7.396